Replimune Group (NASDAQ:REPL) Trading Up 9.5% – Here’s What Happened

Shares of Replimune Group, Inc. (NASDAQ:REPL) were up 9.5% during trading on Thursday . The stock traded as high as $13.56 and last traded at $13.26. Approximately 518,051 shares were traded during mid-day trading, a decline of 50% from the average daily volume of 1,040,285 shares. The stock had previously closed at $12.11.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on REPL. JPMorgan Chase & Co. upped their price target on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. Jefferies Financial Group upped their target price on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. BMO Capital Markets lifted their price target on Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a research note on Friday, November 22nd. Finally, HC Wainwright restated a “buy” rating and set a $17.00 price objective on shares of Replimune Group in a research report on Friday, November 22nd. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $17.29.

Replimune Group Stock Performance

The company has a fifty day moving average of $12.41 and a two-hundred day moving average of $10.96. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The company has a market cap of $867.53 million, a price-to-earnings ratio of -4.16 and a beta of 1.26.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.07. Equities research analysts anticipate that Replimune Group, Inc. will post -2.91 EPS for the current year.

Insider Activity

In other news, CEO Sushil Patel sold 10,000 shares of Replimune Group stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the transaction, the chief executive officer now directly owns 202,014 shares of the company’s stock, valued at approximately $2,509,013.88. This trade represents a 4.72 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Konstantinos Xynos sold 7,246 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the sale, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. The trade was a 6.19 % decrease in their position. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Several institutional investors have recently added to or reduced their stakes in REPL. Bank of New York Mellon Corp boosted its position in shares of Replimune Group by 10.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 180,226 shares of the company’s stock worth $1,622,000 after purchasing an additional 17,471 shares in the last quarter. Rhumbline Advisers boosted its holdings in Replimune Group by 7.2% in the second quarter. Rhumbline Advisers now owns 84,923 shares of the company’s stock worth $764,000 after acquiring an additional 5,732 shares in the last quarter. TD Asset Management Inc grew its stake in Replimune Group by 4.6% in the second quarter. TD Asset Management Inc now owns 249,940 shares of the company’s stock valued at $2,249,000 after acquiring an additional 11,094 shares during the period. Arizona State Retirement System acquired a new position in shares of Replimune Group during the second quarter worth approximately $108,000. Finally, Los Angeles Capital Management LLC raised its position in shares of Replimune Group by 8.1% during the second quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock worth $646,000 after purchasing an additional 5,410 shares during the period. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.